Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Asset Writedowns and Impairment: 2019-2024

Historic Asset Writedowns and Impairment for Heron Therapeutics (HRTX) over the last 6 years, with Sep 2024 value amounting to $828,000.

  • Heron Therapeutics' Asset Writedowns and Impairment rose 437.66% to $828,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $4.4 million, marking a year-over-year increase of 716.05%. This contributed to the annual value of $617,000 for FY2023, which is 195.22% up from last year.
  • According to the latest figures from Q3 2024, Heron Therapeutics' Asset Writedowns and Impairment is $828,000, which was down 74.69% from $3.3 million recorded in Q2 2024.
  • Heron Therapeutics' 5-year Asset Writedowns and Impairment high stood at $3.3 million for Q2 2024, and its period low was $8,000 during Q3 2020.
  • Its 3-year average for Asset Writedowns and Impairment is $463,182, with a median of $154,000 in 2023.
  • Per our database at Business Quant, Heron Therapeutics' Asset Writedowns and Impairment spiked by 2,811.11% in 2020 and then tumbled by 84.22% in 2021.
  • Quarterly analysis of 5 years shows Heron Therapeutics' Asset Writedowns and Impairment stood at $786,000 in 2020, then crashed by 84.22% to $124,000 in 2021, then tumbled by 36.29% to $79,000 in 2022, then soared by 94.94% to $154,000 in 2023, then spiked by 437.66% to $828,000 in 2024.
  • Its last three reported values are $828,000 in Q3 2024, $3.3 million for Q2 2024, and $170,000 during Q1 2024.